- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.06. | Nexalin Technology, Inc.: Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS Platform | 1 | GlobeNewswire (USA) | ||
| 17.06. | Nexalin Technology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | Nexalin Technology, Inc.: Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life ... | 219 | GlobeNewswire (Europe) | Study using Nexalin's proprietary DIFS 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results... ► Artikel lesen | |
| NEXALIN TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 10.06. | EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life | 2 | Benzinga.com | ||
| 04.06. | Nexalin receives U.S. patent for neurostimulation method | 1 | Investing.com | ||
| 04.06. | Nexalin erhält US-Patent für Neurostimulationsverfahren gegen Angst, Depression und Schlaflosigkeit | 1 | Investing.com Deutsch | ||
| 04.06. | Nexalin Technology, Inc.: Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia | 208 | GlobeNewswire (Europe) | Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin's proprietary position in non-invasive frequency-based deep-brain neurostimulation... ► Artikel lesen | |
| 27.05. | Nexalin Technology: EPS übertrifft Schätzungen - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 21.05. | Nexalin: $1.3 Million PONM Acquisition Expands AI-Integrated Neurostimulation Platform Ahead Of FDA Trial | 1 | pulse2.com | ||
| 21.05. | Nexalin Technology, Inc.: Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for ... | 3 | GlobeNewswire (USA) | ||
| 19.05. | Nexalin Technology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.05. | Nexalin Technology, Inc.: Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial | 441 | GlobeNewswire (Europe) | HOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( (Nasdaq: NXL) ("Nexalin" or the "Company"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the... ► Artikel lesen | |
| 08.05. | Nexalin Technology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.04. | Nexalin Technology, Inc.: Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia | 2 | GlobeNewswire (USA) | ||
| 22.04. | Nexalin Technology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | Nexalin announces pivotal insomnia trial, targets Q2 enrollment | 1 | Investing.com | ||
| 22.04. | Nexalin Technology, Inc.: Nexalin Technology Advances Pivotal Clinical Trial of HALO Clarity Toward Q2 2026 Enrollment | 292 | GlobeNewswire (Europe) | HOUSTON, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the... ► Artikel lesen | |
| 15.04. | Nexalin Technology, Inc.: Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China | 286 | GlobeNewswire (Europe) | HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the... ► Artikel lesen | |
| 09.04. | Nexalin Technology, Inc.: Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents | 1 | GlobeNewswire (USA) | ||
| 09.04. | EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device | 2 | Benzinga.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PLUS THERAPEUTICS | 3,310 | -4,34 % | Plus Therapeutics Inc.: Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide CSF Assay Platform | HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company") and Genomic Testing Cooperative, LCA ("GTC") today announced a collaboration... ► Artikel lesen | |
| ORGANON | 11,790 | 0,00 % | Samsung Bioepis and Organon Broaden Biosimilar Access in Australia Through Expanded Commercialisation Agreement | ||
| QUIDELORTHO | 15,070 | -5,07 % | QuidelOrtho Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| NANO-X IMAGING | 1,120 | +7,69 % | NANO-X IMAGING LTD: New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026 | New SCCT abstracts from Brigham and Women's Hospital highlight the performance and clinical utility of Nanox.AI's FDA-cleared cardiac AI solution, showing high agreement with expert assessment and its... ► Artikel lesen | |
| ROCKWELL MEDICAL | 6,125 | +6,89 % | XFRA RWM: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILROCKWELL MEDICAL... ► Artikel lesen | |
| NUWELLIS, INC | 2,780 | 0,00 % | Nuwellis, Inc.: Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies | MINNEAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 19,230 | 0,00 % | PROCEPT BioRobotics to Report Second Quarter 2026 Financial Results on August 4th, 2026 | ||
| NEURONETICS | 1,565 | +0,32 % | Neuronetics Appoints Robert Greene as Senior Vice President Sales | MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of... ► Artikel lesen | |
| PULSE BIOSCIENCES | 23,800 | -0,83 % | Pulse Biosciences, Inc.: Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation | U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary... ► Artikel lesen | |
| OPTIMIZERX | 6,720 | +0,90 % | OptimizeRx Corporation: OptimizeRx Launches CopayCue, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent | WALTHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage... ► Artikel lesen | |
| ORTHOFIX MEDICAL | 10,200 | +6,81 % | CMS-Kehrtwende bei Kostenerstattung: Canaccord bestätigt "Buy"-Rating für Orthofix Medical | ||
| PAVMED | 5,060 | -0,98 % | PAVmed Inc.: PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results | Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission
Lucid Diagnostics continued building... ► Artikel lesen | |
| OWLET | 5,590 | -4,12 % | Owlet Announces New $25 Million Credit Facility With Wells Fargo | ||
| PICARD MEDICAL | 0,141 | -11,41 % | Picard Medical, Inc.: Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program | TUCSON, Ariz., July 15, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard Medical" or the "Company"), parent company of SynCardia Systems, LLC ("SynCardia"), maker of the... ► Artikel lesen | |
| QTREX QUANTUM | 1,255 | 0,00 % | QTREX Quantum Ltd.: QTREX Appoints Dr. Shlomit Chappel-Ram, Veteran AME R&D Executive, as Independent Director |
NEXALIN TECHNOLOGY INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,480 Euro und damit +6,27 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXALIN TECHNOLOGY INC finden Sie auf Wallstreet Online.